(Q39030388)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Giorgio de Stefano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Raffaella Tortora

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Nunzia Farella

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Luigi Addario

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Filippo Lampasi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Alfonso Galeota Lanza

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Gabriella Cordone

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Michele Imparato

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Nicola Caporaso

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

943-951

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25760975%20AND%20SRC:MED&resulttype=core&format=json

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Molecular mechanisms of sorafenib action in liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291

Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.291